Adocia Adocia
  • Adocia
    • About
    • History
    • Management
    • Board of directors
    • Advisory board
  • Products and platforms
    • Pipeline
    • Technology Platforms
  • Careers
    • The « Adocians »
    • HR policy
    • Work environment
    • Join us
  • Partnering
  • Investors
  • Media
  • Contact
    • Contact us
    • Map and accessibility
  • Investors
    • Regulated information
    • Stock information
    • Corporate governance
    • General meeting
  • Media
    • Press releases
    • Media
  • EN
    • FR

BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)

Previous articleBioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
Next articleBioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
Adocia
  • Adocia
  • Products and platforms
  • Careers
  • Partnering
  • Investors
  • Media
  • Contact
Contact us
+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

  • Site plan
  • Legal notice
  • Privacy policy and cookies policy
  • Managing cookies
Website by Un Brin de CampagneUn Brin de Campagne